Schedule 13G ownership disclosure

ALIGOS THERAPEUTICS INC

Security class unavailable · CUSIP: 01626L105

Event date: 2022-02-04

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
3,213,300
Percent of class
7.5000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000935836-22-000180
Form type
SC 13G
Filer
Aligos Therapeutics, Inc.
CIK
CIK 1799448
Filed
Feb 14, 2022
Reporting period
Feb 04, 2022
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub